MUMBAI, India, July 13 -- Intellectual Property India has published a patent application (202617071991 A) filed by Chiesi Farmaceutici S. P. A. on June 10, 2026, for Heterocyclic Derivatives As Janus Kinase Inhibitors.
Inventors include Accetta, Alessandro; Cuzzolin, Alberto; Elenkov, Ivaylo Jivkov; Mesic, Milan; and Radoevic, Ela.
The application for the patent was published on July 10, 2026, under issue no. 28/2026.
Abstract: The present invention relates to compounds that are cyclic carbamate and ureas benzo-morpholine and benzo-thiomorpholine derivatives of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
Disclaimer: Curated by HT Syndication.
